CLINICAL RESEARCH ON DRUG ABUSE

描述：(申请人摘要) 这是一份KO2独立科学家奖(ISA)的申请书 国家药物滥用研究所。申请者是埃里克·斯特雷恩，一名 约翰霍普金斯大学精神病学系内科研究员 大学医学院。斯特拉特博士将他的职业生涯献给了 关于药物滥用和药物滥用患者治疗的研究， 他的主要兴趣集中在开发治疗癌症的药物上。 阿片类药物和可卡因依赖的治疗。这项工作包括了人类 实验室研究和临床试验测试的有效性 治疗药物滥用障碍的药物。一共有六个 将通过以下途径实现的短期和两个长期职业目标 该ISA提供的支持。短期职业目标是：1) 开展与以下相关的临床药理学和治疗评价研究 治疗药物滥用的药物研究进展 障碍，2)研究正在开发的药物组合 药物滥用障碍的治疗，3)开发方法学 将药物疗法与行为疗法相结合 药物滥用治疗临床试验中的治疗方法，4)研究 阿片类药物与可卡因联合应用的治疗方法 依赖，5)在新的开发过程中发展专业知识 治疗药物滥用障碍的药物，以及6)至 定期在科学会议上公布研究结果， 同行评议的期刊，以及治疗社区。实现这些目标 短期目标将有助于实现第一个长期目标， 成为药物滥用、治疗和研究方面公认的专家 与药物滥用研究有关的问题。另外，还有一秒钟 长期目标是成为年轻科学家的导师，特别是 作为年轻医生的榜样，有兴趣追求 从事药物滥用研究。本文件中包含的研究计划 应用程序提供了说明性的调查，提供了一种机制 以实现所描述的职业目标。这些研究考察了 丁丙诺啡/纳洛酮合用对人体的药理作用 实验室研究，并测试一种新的药物疗法与一种已知的 有效的行为疗法在门诊临床试验中的应用 可卡因依赖。这项研究将通过行为研究所进行 药理学研究单位(BPRU)，霍普金斯大学 精神病学。斯特拉特博士得到了BPRU、该部的大力支持 和霍普金斯医学院，这个ISA提供了一个 确保他的高产出职业生涯继续的机制 药物滥用研究。因此，这一ISA代表了一项很好的投资 奈达。

DESCRIPTION: (Applicant's Abstract) This is an application for a KO2 Independent Scientist Award (ISA) from the National Institute on Drug Abuse. The applicant is Eric Strain, a physician-researcher in the Department of Psychiatry at Johns Hopkins University School of Medicine. Dr. Strain has devoted his career to research on drug abuse and to treatment of substance abusing patients, with his primary interest focused upon the development of medications for the treatment of opioid and cocaine dependence. This work has included human laboratory studies as well as clinical trials testing the efficacy of medications for the treatment of substance abuse disorders. There are six short-term and two long-term career goals that will be accomplished through the support provided by this ISA. Short-term career goals are: 1) to conduct clinical pharmacology and treatment-evaluation research pertinent to the development of medications for the treatment of substance abuse disorders, 2) to study medication combinations being developed for the treatment of substance abuse disorders, 3) to develop methodologies integrating pharmacotherapies with behavioral therapies in clinical trials of substance abuse treatments, 4) to study treatment approaches for patients with combined opioid and cocaine dependence, 5) to develop expertise in the development process of new medications for the treatment of substance abuse disorders, and 6) to regularly present results from studies at scientific meetings, in peer-reviewed journals, and to the treatment community. Achieving these short-term goals will contribute to accomplishing the first long-term goal, to become a recognized expert in drug abuse, its treatment, and research issues related to the study of substance abuse. In addition, a second long-term goal is to serve as a mentor to young scientists, and especially function as a role model for young physicians interested in pursuing a career in substance abuse research. The Research Plan included in this application provides illustrative investigations that provide a mechanism for achieving the career goals described. These studies examine the pharmacological effects of buprenorphine/naloxone combinations in human laboratory studies, and test a novel pharmacotherapy combined with a known and effective behavioral therapy in an outpatient clinical trial treating cocaine dependence. This research will be conducted through the Behavioral Pharmacology Research Unit (BPRU), a component of the Hopkins Department of Psychiatry. Dr. Strain has the strong support of the BPRU, the Department of Psychiatry, and the Hopkins School of Medicine, and this ISA provides a mechanism for ensuring the continuation of his highly productive career in substance abuse research. Thus, this ISA represents a good investment by NIDA.